Ethanolamine compounds
Patent 4853381 Issued on August 1, 1989. Estimated Expiration Date: 
October 15, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
October 15, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2308232 2900415 3644353 3818101 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives N-(3-phenoxy-2-hydroxy-propyl)-N-(2-phenyl-2-hydroxy-ethyl)-amines Arylmethoxy-, arylmethylthio-, heteroarylmethoxy-, and heteroarylmethylthio-alkylaminoalcohols Secondary amines, their preparation and use in pharmaceutical compositions Patent #: 4396627 InventorsAssigneeApplicationNo. 06/919122 filed on 10/15/1986US Classes:514/211.15, Additional nitrogen containing hetero ring attached directly or indirectly to the seven-membered hetero ring by nonionic bonding514/183, Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI514/211.01, Hetero ring contains seven members including nitrogen, carbon and chalcogen514/212.01, Hetero ring is seven-membered consisting of one nitrogen and six carbons514/217.07, Polycyclo ring system having the additional six-membered hetero ring as one of the cyclos514/218, Hetero ring is seven-membered consisting of two nitrogens and five carbon atoms514/228.8, Hetero ring is six-membered and includes at least nitrogen and oxygen as ring hetero atoms (e.g., monocyclic 1,2- and 1,3-oxazines, etc.)514/241, Hetero ring is six-membered consisting of three nitrogens and three carbon atoms514/247, Hetero ring is six-membered consisting of two nitrogens and four carbon atoms (e.g., pyridazines, etc.)514/311, Quinolines (including hydrogenated)514/315, Piperidines514/359, Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)514/365, 1,3-thiazoles (including hydrogenated)514/374, 1,3-oxazoles (including hydrogenated)514/385, 1,3-diazoles514/408, The five-membered hetero ring consists of one nitrogen and four carbons514/522, The cyano is bonded directly to a benzene ring514/523, Additional nitrogen other than cyano514/557, Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.)514/562, Sulfur nonionically bonded514/595, Benzene ring containing514/597, Benzene ring is part of a substituent which contains nitrogen514/600, Sulfamides (i.e., N-(O=)S(=O)-N)514/601, Sulfonamides (i.e., Q-(O=)S(=O)-N, wherein Q is a substituent and wherein any substituent attached to the nitrogen will be referred to as E)514/629, R is hydrogen or a lower saturated alkyl of less than seven carbons514/649, Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain514/651, Ether oxygen is part of the chain514/826ASTHMAExaminersPrimary: Raymond, Richard L.Assistant: Covington, Raymond Attorney, Agent or FirmInternational ClassesC07C 49/255 (20060101)C07C 49/82 (20060101) C07C 49/00 (20060101) C07C 45/00 (20060101) C07C 45/67 (20060101) C07C 45/68 (20060101) C07D 215/26 (20060101) C07D 215/00 (20060101) C07D 295/00 (20060101) C07D 295/096 (20060101) Foreign Application Priority Data1984-04-17 GBAbstractThe invention provides compounds of the general formula (I) ##STR1## whereinAr represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms, or the groups C1-6 alkyl, C1-6 alkoxy, nitro, --(CH2)q R [where R is hydroxy, --NR3 R4 (where R3 and R4 each represent a hydrogen atom or a C1-4 alkyl group, or --NR3 R4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O--, or --S-- or a group --NH-- or --N(CH3)--), --NR5 COR6 (where R5 represents a hydrogen atom or a C1-4 alkyl group, and R6 represents a hydrogen atom or a C1-4 alkyl, C1-4 alkoxy, phenyl or --NR3 R4 group), --NR5 SO2 R7 (where R7 represents a C1-4 alkyl, phenyl or --NR3 R4 group), --COR8 (where R8 represents hydroxy, C1-4 alkoxy or --NR3 R4), --SR9 (where R9 is a hydrogen atom, or a C1-4 alkyl or phenyl group), --SOR9, SO2 R9, or --CN, and q represents an integer from 0 to 3], --(CH2)r R10 (where R10 is a C1-4 alkoxy group and r represents an integer from 1 to 3) or --O(CH2)t R11 (where R11 represents a hydroxy or C1-4 alkoxy group and t is an integer 2 or 3), or Ar is a phenyl ring substituted by an alkylenedioxy group of formula --O(CH2)p O-- where p represents an integer 1 or 2;Q represents a group of formula ##STR2## where Ra represents a hydrogen atom or a C1-3 alkyl group,Rb represents ##STR3## and Rc represents ##STR4## where Rd represents a straight or branched C2-3 alkylene chain; R1 and R2 each represent a hydrogen atom or a C1-3 alkyl group with the proviso that the sum total of carbon atoms in R1 and R2 is not more than 4;X represents a C1-7 alkylene, C2-7 alkenylene or C2-7 alkynylene chain; andY represents a bond or a C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is 2-10,and physiologically acceptable salts and solvates (e.g. hydrates) thereof.The compounds of formula (I) have a stimulant action at 댢 -adrenoreceptors and are useful, in particular, in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.Field of SearchEther oxygen is part of the chain | |
